Paydirt
NMRA
Ticker

Neumora Therapeutics, Inc.

NMRA · Healthcare · Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, ne…

Neumora Therapeutics, Inc. (NMRA), in the Healthcare sector, has 5 disclosed filings on Paydirt over the trailing twelve months from 4 corporate insiders: 3 purchases and 2 sales. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed Aug 20 and filed Aug 21. The most active filer was Daljit Singh Aurora with 2 filings.

Add to watchlist
Filings, ttm
5
3 buys · 2 sells
Traders, ttm
4
4 insiders
Volume, ttmiDollar value disclosed in the window
$15.5M
estimated for Congress, as filed for insiders
Median delay
2d
execution to disclosure
Last traded
Aug 20
Filed Aug 21
ADViAverage daily dollar volume
$3.2M
market data
Share price · 12M
$1.39 (-19.7%)
$3.59$2.25$0.92Sep 22 2025Mar 12Aug 28

Adjusted for splits and dividends.

Volume by month
$15.0M$7.5M$0Oct 2024Apr 2025Oct 2025Apr 2026Oct 2025 · buys $15.0MNov 2025 · sells $307KAug 2026 · sells $204K
Buys $15.0M Sells $511K

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed
DA Daljit Singh Aurora See Remarks 2 filings AL ARCH Venture Partners X, LLC 10% owner 1 filing AL ARCH Venture Partners XII, LLC 10% owner 1 filing KB Kristina Burow Director 1 filing MF Matthew K Fust Director 1 filing RL Robert A. Lenz Head of R&D 1 filing
Recent filings
Daljit Singh AuroraSALE See Remarks $204K
134,452 sh across 2 lots
Exec Aug 20
Filed Aug 21 · 7:10 PM ET Daljit Singh AuroraSALE See Remarks $307K
114,703 sh × $2.68
Exec Nov 11 2025
Filed Nov 13 2025 · 5:30 PM ET Kristina BurowPURCHASE Director $5.0M
1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:22 PM ET ARCH Venture Partners XII, LLCPURCHASE 10% owner $5.0M
1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:21 PM ET ARCH Venture Partners X, LLCPURCHASE 10% owner $5.0M
1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:19 PM ET Matthew K FustSALE Director –
21,788 sh across 2 lots · price not plausible
Exec Oct 17 2024
Filed Oct 18 2024 · 5:30 PM ET Robert A. LenzSALE Head of R&D –
8,260 sh · price not plausible
Exec Oct 10 2024
Filed Oct 11 2024 · 5:30 PM ET Robert A. LenzSALE Head of R&D $493K
41,464 sh across 2 lots
Exec Sep 17 2024
Filed Sep 19 2024 · 5:30 PM ET Robert A. LenzSALE Head of R&D $377K
32,948 sh × $11.43
Exec Sep 12 2024
Filed Sep 16 2024 · 5:30 PM ET